Comparative Studies Of Conbercept With Ranibizumab For The Treatment Of Macular Edema Due To Central Retinal Vein Occlusion

Objective:To observe the therapeutic efficacy of intravitreal injection of conbercept and ranibizumab for the treatment of macular edema due to central retinal vein occlusion(CRVO).Methods:According to the standards,sixty patients(60 eyes)diagnosed with macular edema due to CRVO in The Second Affiliated Hospital of Nanchang University were randomly divided into group A,group B and group C,each group with 20 eyes.Group A(the laser group)was treated merely by pan-retinal photocoagulation;Group B(the ranibizumab group)was treated by intravitreal injection of ranibizumab 0.5mg(0.05 m L)combined with Pan-retinal photocoagulation treatment,monthly for three times;Group C(the conbercept group)was treated by intravitreal injection of conbercept 0.5mg(0.05 m L)combined with pan-retinal photocoagulation treatment,monthly for three times.Group B and Group C were received Pan-retinal laser photocoagulation after 1wk of the first injection.Out-patient follow-up had been carried out in the 1st,2nd,3rd,6th,9th and 12 th months post-therapy.The best-corrected visual acuity(BCVA),the central macular thickness(CMT)measured by optical coherence tomography(OCT)and the intraocular pressure(IOP),meanwhile observe the change of fundus fluorescein angiography(FFA)in the 3rd,6th,9th and 12 th months were observed.Results:1.initial value:The intraocular pressure,age,gender,course,systolic pressure,diastolic pressure of patients pretherapy in group A,B and C did not differ significantly between each other.Preoperative CMT and BCVA of patients in group A,B and C did not differ significantly either.2.BCVA(ETDRS): The BCVA pretherapy of group A,group B,group C were(41.12 ± 4.90)(40.50 ± 5.42)(40.72 ± 5.22),and improved to(47.50 ± 3.02)(57.34 ±2.78)(58.45 ± 5.12)12 months after the treatment.There was statistical significance regarding the BCVA pretherapy and posttherapy in all the three groups(P<0.05).During the treatment the average BCVA of group C and B were significantly better than group A(P<0.05);there was no significant difference of the BCVA between group B and group C(P>0.05).At the last follow-up,the efficacy of group B(95%)and group C(90%)were significantly better than that of group A(35%)(P<0.05);there was no significant difference between group B(95%)and group C(90%)(P>0.05).2、CMT(um): The mean CMT pretherapy of group A,group B and group C were(717.50±185.54)um(729.54±168.00)um(736.68±175.82)um,and decreased to(515.63±108.14)um(275.50±77.03)um(285.20±87.69)um 12 months after the treatment.There was statistical significance regarding the CMT pretherapy and posttherapy in all the three groups(P<0.05).The mean CMT of group A and B posttherapy were significantly better than that of group A(P<0.05);there was no significant difference between group B and group C(P>0.05).3.FFA: In the last follow-up,the efficacy of group B(95%)and group C(90%)were significantly better than that of group A(70%),there was no significant difference between group B and group C(P>0.05).4.Injection times: The number of average injection times for ranibizumab was(4.79±0.89),however,it was(4.57±0.85)for conbercept,there was no significant difference between the two groups(P>0.05).Conclusions:Both the intravitreal injection of ranibizumab and conbercept combined with pan-retinal laser photocoagulation for treating CRVO-ME can more effectively increase in visual acuity and decrease in central macular thickness than pan-retinal laser photocoagulation alone,there was no significant difference between ranibuzumab and conbercept for the treatment of macular edema due to central retinal vein occlusion(CRVO).